MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318792 | Name: Tasosartan
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tasosartan is an angiotensin II receptor antagonist.

Chemical Structure

Tasosartan
Tasosartan
CAS#145733-36-4

Theoretical Analysis

MedKoo Cat#: 318792

Name: Tasosartan

CAS#: 145733-36-4

Chemical Formula: C23H21N7O

Exact Mass: 411.1808

Molecular Weight: 411.47

Elemental Analysis: C, 67.14; H, 5.14; N, 23.83; O, 3.89

Price and Availability

Size Price Availability Quantity
1g USD 3,850.00
2g USD 5,450.00
5g USD 8,650.00
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
UNII 48G92V856H; UNII48G92V856H; UNII-48G92V856H; Tasosartan;
IUPAC/Chemical Name
8-((2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2,4-dimethyl-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one
InChi Key
ADXGNEYLLLSOAR-UHFFFAOYSA-N
InChi Code
InChI=1S/C23H21N7O/c1-14-18-11-12-21(31)30(23(18)25-15(2)24-14)13-16-7-9-17(10-8-16)19-5-3-4-6-20(19)22-26-28-29-27-22/h3-10H,11-13H2,1-2H3,(H,26,27,28,29)
SMILES Code
O=C1CCC2=C(C)N=C(C)N=C2N1CC3=CC=C(C4=CC=CC=C4C5=NN=NN5)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 411.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zuo H, Li T, Zhang D, Ma J, Zhang Z, Ou Y, Lian X, Yin J, Li Q, Zhao X. Enhancing Chromatographic Performance of Immobilized Angiotensin II Type 1 Receptor by Strain-Promoted Alkyne Azide Cycloaddition through Genetically Encoded Unnatural Amino Acid. Anal Chem. 2022 Nov 15;94(45):15711-15719. doi: 10.1021/acs.analchem.2c03130. Epub 2022 Nov 1. PMID: 36318741. 2: Awad IE, Abu-Saleh AAA, Sharma S, Yadav A, Poirier RA. High-throughput virtual screening of drug databanks for potential inhibitors of SARS-CoV-2 spike glycoprotein. J Biomol Struct Dyn. 2022 Mar;40(5):2099-2112. doi: 10.1080/07391102.2020.1835721. Epub 2020 Oct 25. PMID: 33103586; PMCID: PMC7643424. 3: Mujwar S, Deshmukh R, Harwansh RK, Gupta JK, Gour A. Drug Repurposing Approach for Developing Novel Therapy Against Mupirocin-Resistant Staphylococcus aureus. Assay Drug Dev Technol. 2019 Oct;17(7):298-309. doi: 10.1089/adt.2019.944. PMID: 31634019. 4: Korkes H, Oliveira LG, Berlinck L, Borges AF, Goes FS, Watanabe S, Landman C, Sass N. PP138. Human fetal malformations associated with the use of angiotensin II receptor antagonist. Pregnancy Hypertens. 2012 Jul;2(3):314-5. doi: 10.1016/j.preghy.2012.04.249. Epub 2012 Jun 13. PMID: 26105460. 5: Elokdah HM, Friedrichs GS, Chai SY, Harrison BL, Primeau J, Chlenov M, Crandall DL. Novel human metabolites of the angiotensin-II antagonist tasosartan and their pharmacological effects. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1967-71. doi: 10.1016/s0960-894x(02)00303-7. PMID: 12113820. 6: Unger T. Pharmacology of AT1-receptor blockers. Blood Press Suppl. 2001;(3):5-10. doi: 10.1080/08037050152518302. PMID: 11683476. 7: Maillard MP, Rossat J, Brunner HR, Burnier M. Tasosartan, enoltasosartan, and angiotensin II receptor blockade: the confounding role of protein binding. J Pharmacol Exp Ther. 2000 Nov;295(2):649-54. PMID: 11046101. 8: Viigimaa M, Allikmets K, Parik T, Skards J, Franken A, Häss G. Tasosartan and hydroclorothiazide as combination therapy in the treatment of severe essential hypertension: comparison with enalapril. Tasosartan Study Group. Cardiovasc Drugs Ther. 2000 Aug;14(4):447-9. doi: 10.1023/a:1007876519124. PMID: 10999653. 9: Dina R, Jafari M. Angiotensin II-receptor antagonists: an overview. Am J Health Syst Pharm. 2000 Jul 1;57(13):1231-41. doi: 10.1093/ajhp/57.13.1231. Erratum in: Am J Health Syst Pharm 2000 Nov 15;57(22):2036. Erratum in: Am J Health Syst Pharm 2001 May 15;58(10):864. PMID: 10902066. 10: Andrawis NS, Battle MM, Klamerus KJ, Burghart PH, Neefe L, Weinryb I, Mayer P, Abernethy DR. A pharmacokinetic and pharmacodynamic study of the potential drug interaction between tasosartan and atenolol in patients with stage 1 and 2 essential hypertension. J Clin Pharmacol. 2000 Mar;40(3):231-41. doi: 10.1177/00912700022008892. PMID: 10709151. 11: Hines J, Fluharty SJ, Sakai RR. The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling. Eur J Pharmacol. 1999 Nov 12;384(1):81-9. doi: 10.1016/s0014-2999(99)00662-7. PMID: 10611423. 12: Timmermans PB. Pharmacological properties of angiotensin II receptor antagonists. Can J Cardiol. 1999 Nov;15 Suppl F:26F-8F. PMID: 10579749. 13: Timmermans PB. Angiotensin II receptor antagonists: an emerging new class of cardiovascular therapeutics. Hypertens Res. 1999 Jul;22(2):147-53. doi: 10.1291/hypres.22.147. PMID: 10487332. 14: Rhéaume C, Waib PH, Lacourcière Y, Cléroux J. Effects of angiotensin antagonism with tasosartan on regional and systemic haemodynamics in hypertensive patients. J Hypertens. 1998 Dec;16(12 Pt 2):2085-9. doi: 10.1097/00004872-199816121-00034. PMID: 9886901. 15: Neutel JM, Buckalew V, Chrysant SG, Mroczek WJ, Ruff DA, Weber M. Efficacy and tolerability of tasosartan, a novel angiotensin II receptor blocker: results from a 10-week, double-blind, placebo-controlled, dose-titration study. Tasosartan Investigators Group. Am Heart J. 1999 Jan;137(1):118-25. doi: 10.1016/s0002-8703(99)70467-9. PMID: 9878944. 16: Ellingboe JW, Collini MD, Quagliato D, Chen J, Antane M, Schmid J, Hartupee D, White V, Park CH, Tanikella T, Bagli JF. Metabolites of the angiotensin II antagonist tasosartan: the importance of a second acidic group. J Med Chem. 1998 Oct 22;41(22):4251-60. doi: 10.1021/jm970690q. PMID: 9784100. 17: Lacourcière Y, Pool JL, Svetkey L, Gradman AH, Larochelle P, de Champlain J, Smith WB. A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial of four doses of tasosartan in patients with essential hypertension. Tasosartan Investigator's Group. Am J Hypertens. 1998 Apr;11(4 Pt 1):454-61. doi: 10.1016/s0895-7061(97)00487-1. PMID: 9607384. 18: Brunner HR. The new angiotensin II receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations. Am J Hypertens. 1997 Dec;10(12 Pt 2):311S-317S. doi: 10.1016/s0895-7061(97)00391-9. PMID: 9438775. 19: Ellingboe JW, Antane M, Nguyen TT, Collini MD, Antane S, Bender R, Hartupee D, White V, McCallum J, Park CH, et al. Pyrido[2,3-d]pyrimidine angiotensin II antagonists. J Med Chem. 1994 Feb 18;37(4):542-50. doi: 10.1021/jm00030a013. PMID: 8120871.